Mandate

Vinge advises Altor and management sellers in divestment of Euro Cater

April 26, 2013

Vinge is advising Altor Fund II G.P and management sellers in connection with the divestment of Euro Cater to reinvesting employees and Intermediate Capital Group plc (ICG). Euro Cater is a leading Nordic food service company, distributing food and non-food products to hotels, restaurants and other professional kitchens. Euro Cater conducts operations in Denmark and Sweden and has around 1,750 employees. Altor invested in Euro Cater in 2006, and since then Euro Cater’s EBITDA has increased from DKK 200 million to DKK 500 million. The transaction is subject to approval of relevant competition authorities.

The Vinge team acts as local counsel to the sellers in the transaction, and includes partner Bo Adrianzon and associates Johan Steen, Ulrich Ziche, Oscar Rydén and Karin Isacson.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026